Search results
Results from the WOW.Com Content Network
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.
Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive.He served as an Associate Professor of Medicine at UCLA School of Medicine (Los Angeles, CA) for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the ...
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Truist initiated ...
BioNTech said partner Pfizer will reimburse it for up to $170 million of the royalties payable to Penn and $364.5 million of the royalties paid to the National Institutes of Health (NIH)for 2020 ...
Alexandru Radu Aricescu, known by his middle name, is a Romanian-British molecular neuroscientist based at the MRC Laboratory of Molecular Biology, Cambridge; Prior to 2017, he worked at the Wellcome Trust Centre for Human Genetics at the University of Oxford; in 2016 the University awarded him the title of Professor of Molecular Neuroscience.
BioNTech is scheduled to provide detailed full-year 2024 guidance alongside its 2023 financial results on March 20. ($1 = 0.9141 euros) (Editing by Rachel More and Matthias Williams)
Uğur Şahin (Turkish: [uˈuɾ ʃaː.hin]; born 19 September 1965 [3]) is a German oncologist and immunologist.He is the co-founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19.
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.